Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how scarcity shapes life and death decisions.

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

Fresh tax cuts, an instant $1,000 tax reduction and cheaper medicines: here's what the federal government's latest budget means for Australians.

Hims launched generic Semaglutide in Canada, opening a lower-cost alternative to Novo Nordisk’s Ozempic and Wegovy. ・Health Canada recently approved the first generic semaglutide products in the G7.

Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.

Precigen's PAPZIMEOS wins early FDA approval with rapid insurer/physician uptake, a strong growth outlook, and improving EPS.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimbursement denials 83% of target accounts on formulary or in review ...

An error has occurred. Please try again. With a The Portland Press Herald subscription, you can gift 5 articles each month. It looks like you do not have any active ...